The supplied filings document one FDA pathway record for BAAT Medical Products B.V.: GANNET®, cleared under K262184 with decision code SESE and the description Substantially Equivalent. The submission was received 29 June 2026 and decided 22 October 2026, with product code JDO, orthopedic advisory committee, and a summary statement. The applicant address on the filing is F. Hazemeijerstraat 800, Hengelo, Netherlands, which is a filing address rather than a verified headquarters. The collection holds one linked record, all on the 510(k) pathway, and the single decision is SESE; these are counts of the supplied filings as of the snapshot, not measures of total portfolio, sales or safety performance. [1][8][2]

The cleared device and its components

The GANNET® implant is described in its instructions for use as a device for surgical fixation of femoral neck, trochanteric fractures and stable subtrochanteric fractures. The system comprises three main components: a blade for stable fixation within the femoral head, a barreled side-plate that allows controlled sliding and dynamization, and cortical bone screws for attachment to the femur. The surgical technique repeats that three-part description. [2][3]

An earlier English instructions-for-use revision, dated 28 February 2022, describes Gannet® as a single-use class IIb implant consisting of a blade, an SHS barrel plate and two cortical bone screws, with the blade positioned centrally in the femoral head at an angle of 135 degrees. That revision is a European document and its class designation should not be read as an FDA classification; the FDA record lists device class 2 under regulation 888.3030. [5][1]

Filing scope and dated record

K262184 is the only record in the supplied sample. It is a traditional 510(k) with no third-party review, received 29 June 2026 and decided 22 October 2026, with decision code SESE and the description Substantially Equivalent. The associated openFDA device name is "Device, Fixation, Proximal Femoral, Implant" under product code JDO and regulation number 888.3030, in the orthopedic advisory committee. [1]

A separate openFDA query covering decision dates from 19 October to 31 December 2026 returned 63 results in total and includes the same K262184 entry for BAAT Medical Products B.V. That figure describes the query result set, not BAAT Medical's portfolio. The supplied collection counts one linked record and one SESE decision, and the record sample likewise contains one SESE entry. [8][1]

Instructions, technique and end-user information

The current US instructions for use carry document number BM-005057-EI, version 3, dated 4 November 2026, and state that federal law restricts the device to sale by or on the order of a physician. The matching surgical technique is BM-005056-EI, version 3, dated the same day. The instructions note that the behavior of the device in the MR environment is unknown and that performing an MR exam on a person with the device may result in injury or device malfunction. [2][3]

BAAT Medical's end-user information page states that paper instructions for use are available on request by email, free of charge in the EU and provided within 7 calendar days, and that users should confirm they hold the latest version before use. The same page lists ISO 13485 and Annex IX certificates issued by MedCert and DNV, attributed to that publisher. The surgical technique lists Gannet blade, plate and self-tapping cortical screw part numbers, with ordering through a Gannet distributor. [4][7]

Company context as published

A BAAT Medical news item dated 27 August 2026 describes the Gannet hip implant's path from development to the US market and states that more than 3,000 patients have received the implant, with hospitals in the Netherlands, Belgium and Italy using it. Those figures and claims originate with the company's own publication and are not independently verified in the public documents. No parent, brand or ownership relationship is documented. [6]